| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.18(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$32.18 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
| Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
| Total People Sold |
1 |
1 |
12 |
18 |
| Total Sell Transactions |
1 |
1 |
25 |
69 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Buzy Peter L |
President, Gene Therapy |
• – – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,184 |
45,684 |
|
- |
|
| Chiminski John R |
Chair & CEO |
• • – |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
24,027 |
253,717 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2019-07-15 |
4 |
A |
$53.24 |
$262,313 |
I/I |
4,927 |
4,927 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2019-07-15 |
4 |
D |
$53.24 |
$262,313 |
I/I |
(4,927) |
0 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2019-07-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,927 |
4,927 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2019-07-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,927 |
15,755 |
|
- |
|
| Littlejohns Barry |
President, Biologics & SDD |
• – – |
2019-07-12 |
4 |
AS |
$53.53 |
$853,344 |
D/D |
(15,940) |
37,718 |
|
- |
|
| Littlejohns Barry |
President, Biologics & SDD |
• – – |
2019-07-12 |
4 |
D |
$53.54 |
$1,781,383 |
D/D |
(33,272) |
53,658 |
|
- |
|
| Littlejohns Barry |
President, Biologics & SDD |
• – – |
2019-07-12 |
4 |
OE |
$18.57 |
$952,938 |
D/D |
49,212 |
67,562 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2019-07-11 |
4 |
AS |
$54.04 |
$219,024 |
D/D |
(4,053) |
48,528 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2019-07-11 |
4 |
D |
$54.01 |
$1,028,350 |
D/D |
(19,040) |
52,581 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2019-07-11 |
4 |
OE |
$24.26 |
$741,142 |
D/D |
27,146 |
60,705 |
|
- |
|
| Pravda Ricardo |
SVP, Human ResourcesOfficer |
• – – |
2019-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,383 |
|
- |
|
| Buzy Peter L |
President, Gene Therapy |
• – – |
2019-05-29 |
4 |
B |
$45.13 |
$2,008,285 |
D/D |
44,500 |
44,500 |
2.74 |
- |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2019-05-28 |
4 |
D |
$46.23 |
$216,218 |
D/D |
(4,677) |
37,383 |
|
- |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2019-05-28 |
4 |
OE |
$10.71 |
$101,242 |
D/D |
9,453 |
42,060 |
|
- |
|
| Zippelius Peter |
Director |
– • – |
2019-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
475 |
475 |
|
- |
|
| Morel Donald E Jr |
Director |
– • – |
2019-05-15 |
4 |
B |
$44.44 |
$444,400 |
D/D |
10,000 |
46,958 |
2.39 |
- |
|
| Lucier Gregory T |
Director |
– • – |
2019-05-09 |
4 |
B |
$45.08 |
$90,160 |
D/D |
2,000 |
38,822 |
2.39 |
- |
|
| Gennadios Aristippos |
President, Softgel Tech. |
• – – |
2019-03-21 |
4 |
AS |
$42.17 |
$143,089 |
D/D |
(3,392) |
34,726 |
|
- |
|
| Gennadios Aristippos |
President, Softgel Tech. |
• – – |
2019-03-21 |
4 |
D |
$42.16 |
$284,385 |
D/D |
(6,744) |
38,118 |
|
- |
|
| Gennadios Aristippos |
President, Softgel Tech. |
• – – |
2019-03-21 |
4 |
OE |
$10.71 |
$144,885 |
D/D |
13,528 |
44,862 |
|
- |
|
| Miyamoto Lance |
SVP, Human Resources |
• – – |
2019-03-07 |
4 |
S |
$42.49 |
$1,853,378 |
D/D |
(43,619) |
46,799 |
|
- |
|
| Miyamoto Lance |
SVP, Human Resources |
• – – |
2019-03-07 |
4 |
D |
$42.64 |
$3,410,816 |
D/D |
(79,991) |
90,418 |
|
- |
|
| Miyamoto Lance |
SVP, Human Resources |
• – – |
2019-03-07 |
4 |
OE |
$12.14 |
$1,896,337 |
D/D |
123,610 |
130,793 |
|
- |
|
821 Records found
|
|
Page 21 of 33 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.18 (0.34%) 
